The Only 3 Big Pharma Companies Growing Market Share
With worldwide spending on prescription drugs increasing from an estimated $774 billion in 2017 to over $1 trillion in 2022, a rising tide of pharmaceutical sales is lifting a lot of drug company boats and creating plenty of opportunities for investors. Much of the profit from this boom will accrue to riskier, entrepreneurial enterprises specializing in a particular new approach, but among the big pharma companies that conservative investors value for their stability, diversification, and cash generation, there will be relative winners and losers.
According to analysis by market research firm EvaluatePharma, 19 of the top 20 sellers of prescription drugs will grow sales between 2016 and 2022, but only three of them that are publicly traded will increase market share. These three companies are winning in very different ways.
Bristol-Myers Squibb (NYSE: BMY) is projected to barely sneak into the market share winner's circle by increasing its share from 2.3% in 2016 to 2.4% in 2022. To understand the growth drivers that could make the company move ahead of the competition in the next five years, you don't have to look any further than Bristol's lead cancer drug, Opdivo.
Source: Fool.com
